Mum1 clone mum1p

Manufactured by Agilent Technologies

Sourced in Germany, United Kingdom

MUM1 (clone MUM1p) is a laboratory equipment product offered by Agilent Technologies. It serves as a core regulatory protein that plays a role in the differentiation and activation of B-cells and plasma cells. The product's primary function is to facilitate research and analysis related to B-cell and plasma cell development and immune response.

Automatically generated - may contain errors

Lab products found in correlation

13 protocols using mum1 clone mum1p

Immunohistochemical Profiling of Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemical stainings were performed on FFPE tissue using fully automated protocols (DAKO Autostainer Link 48). Staining protocols with antibodies to MYC (clone Y69; Abcam), BCL‐2 (clone 124; DAKO), BCL‐6 (clone PG‐B6p; DAKO), Ki‐67 (MIB‐1; DAKO), MUM‐1(clone MUM1p; DAKO), CD10 (clone 56C6; DAKO) and p53 (DO‐7; DAKO) were performed. The estimation of positive staining for CD10, BCL‐6 and MUM‐1 was based on the Hans algorithm. Cut‐off values of 70% and 40% were used for BCL2 and MYC, respectively, as previously described.16

Abdulla M., Guglielmo P., Hollander P., Åström G., Ahlström H., Enblad G, & Amini R. (2019). Prognostic impact of abdominal lymph node involvement in diffuse large B‐cell lymphoma. European Journal of Haematology, 104(3), 207-213.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Hematoxylin and Eosin (H&E) stained FFPE tissue sections were reviewed to assess cyto-architectural features. Immunohistochemistry and in-situ hybridization was performed with the following panel of antibodies and probes; CD20 (clone MJ1); CD10 (clone 56C6); CD5 (clone 4C7); BCL6 (clone LN22); BCL2 (clone D5); CD21 (clone PA0171); kappa (clone ISH-5748A), lambda (clone ISH-5770A), all from Leica, IL, USA; CD79a (clone AP18); Cyclin D1 (clone SP4-R); CD138 (clone B-A38); CD21 (clone PA0171); IgG (clone 1210208A); IgG4 (clone 1123107A); Ki-67 (clone 30-9), all from Ventana, AZ, USA; and MUM-1 (clone MUM1p) from DAKO, CA, USA. Staining was performed with automated stainers (Ventana Benchmark Ultra and Leica Bond III) and visualized with the UltraView Universal and Bond polymer DAB detection kits according to the manufacturer's protocols.

Ganapathi K.A., Jobanputra V., Iwamoto F., Jain P., Chen J., Cascione L., Nahum O., Levy B., Xie Y., Khattar P., Hoehn D., Bertoni F., Murty V.V., Pittaluga S., Jaffe E.S., Alobeid B., Mansukhani M.M, & Bhagat G. (2016). The genetic landscape of dural marginal zone lymphomas. Oncotarget, 7(28), 43052-43061.

+ Open protocol

+ Expand

Immunohistochemistry Panel for Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry was performed on 4-μm FFPE sections. Antibodies used in the study were CD20 (clone L26, Abcam, cutoff: 30%), CD10 (clone 56C6, Dako, cutoff: 30%), MUM1 (clone MUM1p, Dako), Bcl6 (clone LN22, Dako, cutoff: 30%), Myc (clone Y69; Abcam, cutoff: 40%) and Bcl2 (clone 124; Dako, cutoff: 50%). Cutoff scores for each antibody were described previously [2 (link), 19 (link)].

Wu S., Zhou Y., Hua H.Y., Zhang Y., Zhu W.Y., Wang Z.Q., Li J., Gao H.Q., Wu X.H., Lu T.X, & Hua D. (2018). Inflammation marker ESR is effective in predicting outcome of diffuse large B-cell lymphoma. BMC Cancer, 18, 997.

+ Open protocol

+ Expand

Immunohistochemical Evaluation of Lymphoma Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Immunohistochemistry (IHC) was performed with the Dako Autostainer Link 48, according to the manufacturer’s recommendations, for the antibodies CD10 (clone 56C6 from Dako, diluted 1:20), BCL6 (clone PG-B6p from Invitrogen, diluted 1:100), MUM1 (clone MUM1p from Dako, diluted 1:100), BCL2 (clone 124 Dako, diluted 1:80), and IgM (polyclonal, from Dako, diluted 1:500). The markers were scored positive in case of expression in ≥ 30% of the tumor cells for CD10, BCL6, and MUM1, and in ≥ 50% of the tumor cells for BCL2 and IgM.

Schrader A.M., de Groen R.A., Willemze R., Jansen P.M., Quint K.D., van Wezel T., van Eijk R., Ruano D., Tensen C.P., Hauben E., Woei-A-Jin F.J., Busschots A.M., van den Berg A., Diepstra A., Vermeer M.H, & Vermaat J.S. (2022). Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas. Virchows Archiv, 480(3), 667-675.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Hematologic Malignancies

Check if the same lab product or an alternative is used in the 5 most similar protocols

Formalin-fixed paraffin-embedded tissues were stained with hematoxylin and eosin at the initial diagnosis. Immunohistochemistry was performed using the following panel of monoclonal and polyclonal antibodies: CD20 (clone L26, DAKO, Glostrup, Denmark); CD79a (clone 1.10E + 04, Leica Biosystems, Wetzlar, Germany); PAX5 (clone R1, DAKO); CD10 (clone 56C6, Leica Biosystems); BCL6 (clone P1F6, DAKO); MUM1 (clone MUM1p, DAKO); Ki-67 (clone MIB-1, DAKO); Terminal deoxynucleotidyl transferase (TDT, clone SP150, DAKO); CD2 (clone AB75, DAKO); CD3 (clone LN10, Leica Biosystems); CD4 (clone SP35, DAKO); CD7 (DAKO); CD8 (clone SP16, DAKO); CD1a (clone SP157, DAKO); CD34 (clone QBEnd/10, DAKO); CD43 (clone DF-T1, DAKO); CD99 (clone HO36-1.1, DAKO); CD117 (clone C-KIT, DAKO); CD45 (clone PAN-LCAL, DAKO); CD33 (clone WM-54, DAKO); MPO (clone SP72, DAKO); CD15 (clone C3D-1, DAKO); CD30 (clone Ber-H2, DAKO); CD23 (clone SP23, DAKO); and Epithelial membrane antigen (EMA, clone GP1.4, Leica Biosystems).

Chen L., Wang M., Fan H., Hu F, & Liu T. (2017). Comparison of pediatric and adult lymphomas involving the mediastinum characterized by distinctive clinicopathological and radiological features. Scientific Reports, 7, 2577.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

Haematoxylin–eosin‐stained slides were reviewed and representative tumour cell‐rich cores were taken in triplicate from formalin‐fixed and paraffin‐embedded (FFPE) blocks to build tissue microarrays (TMA). Immunohistochemical stains were performed with Dako EnVision system (Dako, Glostrup, Denmark) following the manufacturer's protocol. The following antibodies (clone, concentration; brand) were used: CD10 (56C6, 1/20; Novocastra, Newcastle, UK), BCL6 (PG‐B6P, 1/30; Dako), MUM1 (clone MUM1p, 1/40; Dako), BCL2 (124, 1/200; Dako) MYC (Y69, 1/100, Epitomics, Burlingame, CA, USA) and CD30 (clone 1G12, 1/20, Novocastra). BCL2 and MYC were scored in 5% increments, and other markers as positive or negative. The cutoff of 30% was applied for CD10, BCL6 and MUM1 according to Hans criteria.⁹ For CD30, the cutoff was 20% and focal positivity was recorded.¹⁰

Baptista M.J., Tapia G., Muñoz‐Marmol A., Muncunill J., Garcia O., Montoto S., Gribben J.G., Calaminici M., Martinez A., Veloza L., Martínez‐Trillos A., Aldamiz T., Menarguez J., Terol M., Ferrandez A., Alcoceba M., Briones J., González‐Barca E., Climent F., Muntañola A., Moraleda J., Provencio M., Abrisqueta P., Abella E., Colomo L., García‐Ballesteros C., Garcia‐Caro M., Sancho J., Ribera J., Mate J, & Navarro J. (2022). Genetic and phenotypic characterisation of HIV‐associated aggressive B‐cell non‐Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications. Histopathology, 81(6), 826-840.

+ Open protocol

+ Expand

Immunohistochemical Analysis of Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC (Figure 6) was performed on 4 μm sections with formalin-fixed paraffin-embedded (FFPE) specimens. Antibodies applied in the study including CD10 (clone 56C6; Dako, cut-off: 30%), MYC (clone Y69; Abcam, cut-off: 40%), BCL2 (clone 124; Dako, cut-off: 50%), BCL6 (clone LN22; Dako, cut-off: 30%), and MUM1 (clone MUM1p; Dako, cut-off: 30%). The COO was classified according to Hans algorithm [32 (link)].

Lu T.X., Fan L., Wang L., Wu J.Z., Miao K.R., Liang J.H., Gong Q.X., Wang Z., Young K.H., Xu W., Zhang Z.H, & Li J.Y. (2015). MYC or BCL2 copy number aberration is a strong predictor of outcome in patients with diffuse large B-cell lymphoma. Oncotarget, 6(21), 18374-18388.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Lymphoma Subtypes

Cited 2 times

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies applied in the study, according to the manufacturer’s instructions, included CD5 (clone EP2952, Abcam, cut-off: 30%), CD10 (clone 56C6, Dako, cut-off: 30%), CD30 (clone CON6D/B5, Abcam, cut-off: 30%), Ki-67 (clone Mib-1, Dako), Myc (clone Y69, Abcam, cut-off: 40%), Bcl2 (clone 124, Dako, cut-off: 50%), Bcl6 (clone LN22, Dako, cut-off: 30%), MUM1 (clone MUM1p, Dako, cut-off: 30%), FOXP1 (clone JC12, Abcam, cut-off: 60%), GCET1 (clone RAM341; Abcam, cut-off: 60%) and LMO2 (clone 1A9-1, Santa Cruz, cut-off: 30%). The cell of origin (COO) was classified according to Hans, Choi, Tally and Visco-Young algorithms. The specific cut-off of each antibody used in different algorithms was described previously21 (link)22 (link)23 (link)24 (link).

Lu T.X., Liang J.H., Miao Y., Fan L., Wang L., Qu X.Y., Cao L., Gong Q.X., Wang Z., Zhang Z.H., Xu W, & Li J.Y. (2015). Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age. Scientific Reports, 5, 12168.

+ Open protocol

+ Expand

Immunohistochemical Profiling of DLBCL

Check if the same lab product or an alternative is used in the 5 most similar protocols

Formalin-fixed, paraffin-embedded tissue samples were available for all the 36 cases and were stained with hematoxylin and eosin (HE) at initial diagnosis. Immunohistochemistry was performed using a panel of monoclonal and polyclonal antibodies, as follows: CD20 (clone L26, DAKO, Glostrup, Denmark); CD79a (clone 1.10E+04, Leica Biosystems, Wetzlar, Germany); PAX5 (clone R1, DAKO); CD10 (clone 56C6, Leica Biosystems); BCL6 (clone P1F6, DAKO); MUM1 (clone MUM1p, DAKO); Ki-67 (clone MIB-1, DAKO); BCL2 (clone 100/D5, DAKO); MYC (DAKO); EBV (DAKO); terminal deoxynucleotidyl transferase (TDT, clone SP150, DAKO); CD3 (clone LN10, Leica Biosystems); CD43 (clone DF-T1, DAKO). MYC was considered as positive when > 40% of tumor cells exhibited staining [20 ]. Positivity threshold was defined at 50% for BCL2 [20 ], and at 30% for CD10, BCL6, and MUM1 [4 (link)]. For sub-classification of DLBCLs, GC immunophenotype was evaluated by antibodies of C10, BCL6 and MUM1 [4 (link)].

Chen L., Al-Kzayer L.F., Liu Y, & Liu T. (2017). B-cell lymphomas involving Waldeyer's ring characterized by distinctive clinical and histopathological features: a comparison of pediatric to adult patients. Oncotarget, 8(7), 11544-11554.

+ Open protocol

+ Expand

Immunohistochemical Profiling of Lymphoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

IHC was performed on 4-μm FFPE sections. The antibodies used were CD10 (clone 56C6, Dako), CD20 (clone L26, Abcam), Bcl6 (clone LN22, Dako), and MUM1 (clone MUM1p, Dako), Myc (clone Y69; Abcam, cut-off: 40%) and Bcl2 (clone 124; Dako, cut-off: 50%) (Figure S1). The cut-off scores for each antibody were described previously9 (link)19 (link). Cases positive for both CD10 and MUM1were classified as DP group. Cases negative for CD10, Bcl6 and MUM1 were defined as TN group. Cases positive for both Myc and Bcl2 or Bcl6 were defined as double expression lymphoma (DEL)19 (link).

Lu T.X., Miao Y., Wu J.Z., Gong Q.X., Liang J.H., Wang Z., Wang L., Fan L., Hua D., Chen Y.Y., Xu W., Zhang Z.H, & Li J.Y. (2016). The distinct clinical features and prognosis of the CD10+MUM1+ and CD10−Bcl6−MUM1− diffuse large B-cell lymphoma. Scientific Reports, 6, 20465.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!